We are delighted to share that the NORDSTAR manuscript “Use of high-dose inhaled corticosteroids and risk of corticosteroid related adverse events in asthma- findings from the NORDSTAR cohort” is now available online, co-authored by Quantify’s Patrik Sandin, Alexandra Cooper, Olivia Ernstsson, and Kirk Geale, PhD.
NORDSTAR is lead by Celeste Porsbjerg at Bispebjerg Hospital in collaboration with Quantify Research, AstraZeneca, Sanofi, GSK and the good people at the Nordic Servere Asthma Network – and manages the world’s largest asthma dataset. Special thanks to Apostolos Bossios, Lauri Lehtimäki, Christer Janson, Hannu Kankaanranta, Anna von Bülow and Susanne Hansen.
The study found that:
🟢 Asthma patients using high-dose (≥800-1599 µg) and very-high-dose (≥1600 µg) ICS had an increased risk of several adverse events (SAEs), including cardiovascular disease, type 2 diabetes, osteoporosis, and pneumonia.
🟢 In contrast, low dose (<800 µg) ICS use did not appear to increase risk for most SAEs.
🟢 The risks associated with high- and very-high dose ICS persisted even in patients not using oral corticosteroids (OCS).
👉 The findings highlight the importance of risk management in those treated with high-dose and very high dose inhaled corticosteroid.
You can read the article in full here:
Want to know more? Get in touch!
